|
|
Next Article 
The biology and treatment of acute lymphoblastic leukemia in adults
EA Copelan and EA McGuire
Department of Internal Medicine, Ohio State University, Columbus.
Despite reports to the contrary, only a small minority of adults with ALL
are currently cured. Results have improved modestly with more intensive
postremission chemotherapy and with tailoring of protocols in individuals
with specific subsets of ALL. The use of growth factors may further improve
treatment results. The performance of allogeneic BMT in first remission is
clearly effective in some individuals, eg, those with Ph1-positive ALL, but
it is unclear whether it is advantageous in most individuals. There are
little data supporting the effectiveness of autotransplantation, as
currently performed in ALL, despite its theoretical potential. Advances in
understanding the biology of ALL have led to new approaches currently under
basic and clinical investigation. These include serial studies of minimal
residual disease by a variety of techniques to tailor treatment, the
development of conjugated MoAbs to lymphoid cell antigens and immunologic
and biochemical approaches to chimeric RNA and peptides generated by
abnormal fusion genes. It seems likely that substantial improvement in the
treatment of adult ALL awaits better characterization of the biology of
this disease. However, some improvement will occur through empirical
clinical research. It is critical that physicians recognize the poor
results with current therapeutic approaches and enter patients into large
well-designed clinical trials.
Volume 85,
Issue 5,
pp. 1151-1168,
03/01/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Nonomura, J. Kikuchi, N. Kiyokawa, H. Ozaki, K. Mitsunaga, H. Ando, A. Kanamori, R. Kannagi, J. Fujimoto, K. Muroi, et al.
CD43, but not P-Selectin Glycoprotein Ligand-1, Functions as an E-Selectin Counter-Receptor in Human Pre-B-Cell Leukemia NALL-1
Cancer Res.,
February 1, 2008;
68(3):
790 - 799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kikuchi, H. Shinohara, C. Nonomura, H. Ando, S. Takaku, H. Nojiri, and M. Nakamura
Not core 2 {beta}1,6-N-acetylglucosaminyltransferase-2 or -3 but -1 regulates sialyl-Lewis x expression in human precursor B cells
Glycobiology,
March 1, 2005;
15(3):
271 - 280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Radich
Targeting ALL leukemia
Blood,
September 1, 2004;
104(5):
1235 - 1236.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Harata, Y. Soda, K. Tani, J. Ooi, T. Takizawa, M. Chen, Y. Bai, K. Izawa, S. Kobayashi, A. Tomonari, et al.
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells
Blood,
September 1, 2004;
104(5):
1442 - 1449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Soda, K. Tani, Y. Bai, M. Saiki, M. Chen, K. Izawa, S. Kobayashi, S. Takahashi, K. Uchimaru, T. Kuwabara, et al.
A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia
Blood,
July 15, 2004;
104(2):
356 - 363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Spiegel, O. Kollet, A. Peled, L. Abel, A. Nagler, B. Bielorai, G. Rechavi, J. Vormoor, and T. Lapidot
Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling
Blood,
April 15, 2004;
103(8):
2900 - 2907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tafuri, C. Gregorj, M. T. Petrucci, M. R. Ricciardi, M. Mancini, G. Cimino, C. Mecucci, A. Tedeschi, G. Fioritoni, F. Ferrara, et al.
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia
Blood,
July 18, 2002;
100(3):
974 - 981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Linker, L. Damon, C. Ries, and W. Navarro
Intensified and Shortened Cyclical Chemotherapy for Adult Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
May 15, 2002;
20(10):
2464 - 2471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Savage and K. H. Antman
Imatinib Mesylate -- A New Oral Targeted Therapy
N. Engl. J. Med.,
February 28, 2002;
346(9):
683 - 693.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Y. Mortuza, M. Papaioannou, I. M. Moreira, L. A. Coyle, P. Gameiro, D. Gandini, H. G. Prentice, A. Goldstone, A. V. Hoffbrand, and L. Foroni
Minimal Residual Disease Tests Provide an Independent Predictor of Clinical Outcome in Adult Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
February 15, 2002;
20(4):
1094 - 1104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
Blood,
June 1, 2001;
97(11):
3361 - 3369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Druker, C. L. Sawyers, H. Kantarjian, D. J. Resta, S. F. Reese, J. M. Ford, R. Capdeville, and M. Talpaz
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
N. Engl. J. Med.,
April 5, 2001;
344(14):
1038 - 1042.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Cornelissen, M. Carston, C. Kollman, R. King, A. W. Dekker, B. Lowenberg, and C. Anasetti
Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome
Blood,
March 15, 2001;
97(6):
1572 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Stock, T. Tsai, C. Golden, C. Rankin, D. Sher, M. L. Slovak, M. G. Pallavicini, J. P. Radich, and D. H. Boldt
Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia
Blood,
April 1, 2000;
95(7):
2364 - 2371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cobaleda, N. Gutierrez-Cianca, J. Perez-Losada, T. Flores, R. Garcia-Sanz, M. Gonzalez, and I. Sanchez-Garcia
A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia
Blood,
February 1, 2000;
95(3):
1007 - 1013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Orfao, G. Schmitz, B. Brando, A. Ruiz-Arguelles, G. Basso, R. Braylan, G. Rothe, F. Lacombe, F. Lanza, S. Papa, et al.
Clinically Useful Information Provided by the Flow Cytometric Immunophenotyping of Hematological Malignancies: Current Status and Future Directions
Clin. Chem.,
October 1, 1999;
45(10):
1708 - 1717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Indraccolo, S. Minuzzo, L. Nicoletti, E. Cretella, M. Simon, G. Papakonstantinou, R. Hehlmann, M. Mion, R. Bertorelle, J. Roganovic, et al.
Mutator Phenotype in Human Hematopoietic Neoplasms and Its Association With Deletions Disabling DNA Repair Genes and bcl-2 Rearrangements
Blood,
October 1, 1999;
94(7):
2424 - 2432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wetzler, R. K. Dodge, K. Mrozek, A. J. Carroll, R. Tantravahi, A. W. Block, M. J. Pettenati, M. M. L. Beau, S. R. Frankel, C. C. Stewart, et al.
Prospective Karyotype Analysis in Adult Acute Lymphoblastic Leukemia: The Cancer and Leukemia Group B Experience
Blood,
June 1, 1999;
93(11):
3983 - 3993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-D. Ludwig, H. Rieder, C. R. Bartram, B. Heinze, S. Schwartz, W. Gassmann, H. Loffler, D. Hossfeld, G. Heil, S. Handt, et al.
Immunophenotypic and Genotypic Features, Clinical Characteristics, and Treatment Outcome of Adult Pro-B Acute Lymphoblastic Leukemia: Results of the German Multicenter Trials GMALL 03/87 and 04/89
Blood,
September 15, 1998;
92(6):
1898 - 1909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui and W. E. Evans
Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
August 27, 1998;
339(9):
605 - 615.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.J. Barrett
Mechanisms of the Graft-versus-Leukemia Reaction
Stem Cells,
July 1, 1997;
15(4):
248 - 258.
[Abstract]
[Full Text]
|
|
|
|
|
